Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 442 across all filing types
Latest filing 2023-02-06 Legal Proceedings Report
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
Lupuzor™ Update
Legal Proceedings Report Classification · 1% confidence The document begins with 'RNS Number' and is dated '06 February 2023'. It contains an update regarding a clinical trial ('Lupuzor™ Update', 'Phase 2/3 adaptive study design') and concludes with standard disclaimers referencing RNS and the London Stock Exchange. This format strongly indicates a regulatory news service announcement. Since it is an update on clinical progress and partnership activities, it is not a formal financial report (like 10-K or IR), nor is it a dividend announcement or management change. It is a general regulatory announcement disseminated via RNS, which fits the 'Regulatory Filings' category as a general disclosure.
2023-02-06 English
TR-1: Notification of major holdings
Major Shareholding Notification Classification · 1% confidence The document explicitly states it is a 'TR-1: Standard form for notification of major holdings' and is distributed via 'RNS Number'. It details an acquisition or disposal of voting rights by a person (Gary Smith) resulting in a change in their holding percentage (crossing a threshold from 3.06% to 2.6239%). This type of filing, which reports changes in significant share ownership, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the classification over the general regulatory filing code.
2023-01-27 English
TR-1: Notification of major holdings
Major Shareholding Notification Classification · 1% confidence The document is clearly identified as an 'RNS Number' filing from 'Immupharma PLC' dated '04 January 2023'. The core content is a 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership thresholds. This directly corresponds to the definition of 'Major Shareholding Notification' (MRQ). Although it is distributed via RNS, the specific content dictates the classification over the general regulatory fallback.
2023-01-04 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1931 characters) and contains the header 'RNS Number : 7118L'. It discusses a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement disseminated via the RNS system, rather than a specific financial report (like 10-K, IR, or ER). Since it is a general regulatory announcement that doesn't fit the specific categories like DIRS, DIV, or DLST, the most appropriate fallback category is Regulatory Filings (RNS).
2023-01-04 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1914 characters) and contains the header 'RNS Number : 7098L'. It announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange and explicitly states that the information is provided by RNS, which is approved by the Financial Conduct Authority (FCA) to act as a Primary Information Provider. This structure—a brief, time-sensitive announcement disseminated via the RNS system—fits the definition of a general regulatory announcement that doesn't fit a more specific financial report category. Therefore, it should be classified as a Regulatory Filing (RNS).
2023-01-04 English
TR-1: Notification of major holdings
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled with 'RNS Number : 5671L' and contains the standard header 'NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)'. Section 2 indicates 'An acquisition or disposal of voting rights' is the reason for notification. Section 7 details changes in the percentage of voting rights held by a shareholder (Lanstead Capital Investors LP). This structure perfectly matches the requirements for a Major Shareholding Notification, which is defined in the provided schema as 'MRQ'. Although it is distributed via RNS, the specific content dictates the classification.
2023-01-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.